Key result
Long-term anticoagulation for non-valvular atrial fibrillation necessitates careful evaluation of bleeding risk to determine if all patients truly require lifelong therapy.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
Supports individualized bleeding risk assessment in non-valvular AF; leaves open optimal anticoagulation duration.
"Bleeding risk during anticoagulation: do all patients with non valvular atrial fibrillation need long-term anticoagulation?." Acta Cardiologica, ahead-of-print(ahead-of-print), pp. 1–2
No takes yet. Share an insight, caveat, or question.
Kounis et al. (2021) studied this question. Long-term anticoagulation for non-valvular atrial fibrillation necessitates careful evaluation of bleeding risk to determine if all patients truly require lifelong therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: